BRAF and intrahepatic cholangiocarcinoma: Considering the possibility of BRAF ICC false-negative cases, and the possibility of BRAF mutations other than V600E in ICC negative cases, BRAF ICC should be applied to FNA samples as a screening tool, and molecular analysis should be considered mandatory in BRAF ICC negative cases.